Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor
- 1 May 2000
- journal article
- Published by Elsevier in Biological Psychiatry
- Vol. 47 (9), 818-829
- https://doi.org/10.1016/s0006-3223(99)00291-7
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- N-Linked Oligosaccharides Are Required for Cell Surface Expression of the Norepinephrine Transporter but Do Not Influence Substrate or Inhibitor RecognitionJournal of Neurochemistry, 2002
- Can the Fatal Toxicity of Antidepressant Drugs be Predicted with Pharmacological and Toxicological Data?Drug Safety, 1998
- Is there a role for a pure noradrenergic drug in the treatment of depression?European Neuropsychopharmacology, 1997
- Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodesEuropean Neuropsychopharmacology, 1997
- Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivoLife Sciences, 1994
- Current advances and trends in the treatment of depressionTrends in Pharmacological Sciences, 1994
- Sexual dysfunction and antidepressantsDepression, 1994
- Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomesLife Sciences, 1993
- Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporterNature, 1991
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973